Possible involvement of nitric oxide in the quinolone-induced tendon lesions in rats

Drugs under Experimental and Clinical Research

Volumn 23, Issue 3-4, 1997, Pages 139-143

  Kashida, Y ^a   Kato, M ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRITE; PEFLOXACIN; QUINOLONE;

ACHILLES TENDON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; TENDON LESION; URINARY EXCRETION;

4-QUINOLONES; ACHILLES TENDON; ANIMALS; ANTI-INFECTIVE AGENTS; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUOROQUINOLONES; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031389854     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Stahlmann R., Lode H. Safety overview: toxicity, adverse affects and drug interaction. In: Andriole V., ed. "The quinolones". Academic Press, London, 1988, pp. 201-235.
2. Bailey R.R., Kirk J.A., Peddie B.A. Norfloxacin-induced rheumatic disease. N.Z. Med. J., 96, 590, 1983.
3. Jorgensen C. et al. Arhropathies et tendinopathie achilléenne induites par la pèfloxacine. A propos d'une observation. Revue du Rhumatisme, 58, 623-625, 1991.
4. Meyboom R.H.B., Olsson S., Knol A., Dekens-Konter J.A.M., De Koning G.H.P. Achilles tendinitis induced by pefloxacin and other fluoroquinolone derivatives. Pharmacoepidemiol. Drug Safety, 3, 185-189, 1994.
5. Royer R.J., Pierfitte C., Netter P. Features of tendon disorders with fluoroquinolones. Therapie, 49, 75-76, 1994.
6. Zabranieck L. et al. Fluoroquinolone-induced tendinopathy: report of 6 cases. J. Rheumatol., 23, 516-520, 1996.
7. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43, 109-142, 1991.
8. Kato M., Takada S., Kashida Y., Nomura M. Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol. Pathol., 23, 385-392, 1995.
9. Ochoa J.B., et al. Nitrogen oxide levels in patients after trauma and during sepsis. Ann. Surg., 214, 621-626, 1991.
10. Green L.C., Tannenbaum S.R., Goldman P. Nitrate synthesis in the germfree and conventional rat. Science, 212, 56-58, 1981.
11. Ialenti A., Moncada S., Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol., 110, 701-706, 1993.
12. Radomski MW., Palmer R.M.J., Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. (USA), 87, 10043-10047, 1997.
13. Hibbs J.B. et al. Synthesis of nitric oxide from a terminal guanidino nitrogen atom of L-arginine: a molecular mechanism regulating cellular proliferation that targets intracellular iron. In: Moncada S., Higgs E.A., eds Nitric oxide from L-arginine: a bioregulatory system Elsevier, Amsterdam, 1990, pp. 189-223.
14. Bochsler P.N., Mason G.L., Olchowy T.W.J., Yang Z. Bacterial lipopolysaccharide-stimulated nitric oxide generation is unrelated to concurrent cytotoxicity of bovine alveolar macrophages. Inflammation, 20, 177-189, 1996.
15. Palmer R.M.J., Bridge L., Foxwell N.A., Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br. J. Pharmacol., 105, 11-12, 1992.